Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 51,115 shares of the company's stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the transaction, the insider now owns 326,904 shares of the company's stock, valued at $307,289.76. This trade represents a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Jonathan Zalevsky also recently made the following trade(s):
- On Tuesday, November 19th, Jonathan Zalevsky sold 7,785 shares of Nektar Therapeutics stock. The stock was sold at an average price of $1.01, for a total transaction of $7,862.85.
Nektar Therapeutics Trading Down 1.3 %
NASDAQ NKTR traded down $0.01 during trading hours on Friday, reaching $0.93. The company's stock had a trading volume of 1,787,229 shares, compared to its average volume of 1,795,548. The business has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.24. Nektar Therapeutics has a 52 week low of $0.46 and a 52 week high of $1.93. The stock has a market cap of $171.23 million, a PE ratio of -1.11 and a beta of 0.57.
Institutional Investors Weigh In On Nektar Therapeutics
A number of hedge funds have recently added to or reduced their stakes in NKTR. Samlyn Capital LLC acquired a new stake in shares of Nektar Therapeutics in the 2nd quarter worth about $11,728,000. Eventide Asset Management LLC increased its stake in shares of Nektar Therapeutics by 24.8% in the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company's stock valued at $12,220,000 after purchasing an additional 1,870,904 shares during the period. Millennium Management LLC raised its holdings in shares of Nektar Therapeutics by 56.1% during the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company's stock valued at $5,778,000 after buying an additional 1,674,924 shares during the last quarter. Nantahala Capital Management LLC boosted its position in shares of Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company's stock worth $5,096,000 after buying an additional 1,634,046 shares during the period. Finally, State Street Corp boosted its position in shares of Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company's stock worth $4,349,000 after buying an additional 355,759 shares during the period. 75.88% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. HC Wainwright assumed coverage on Nektar Therapeutics in a research report on Tuesday, December 10th. They set a "buy" rating and a $6.50 target price on the stock. BTIG Research restated a "buy" rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. Finally, Piper Sandler assumed coverage on Nektar Therapeutics in a research report on Monday, November 4th. They issued an "overweight" rating and a $7.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $4.10.
Check Out Our Latest Analysis on Nektar Therapeutics
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
